GDTC
GDTC
NASDAQ · Biotechnology

Cytomed Therapeutics Ltd

$1.00
-0.03 (-2.91%)
Financial Highlights (FY 2026)
Revenue
65.9K
Net Income
-2,396,269
Gross Margin
Profit Margin
-3,621.2%
Rev Growth
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.2% 48.2% 48.2%
Operating Margin -3,628.6% -13.7% -13.7% -16.6%
Profit Margin -3,621.2% -13.7% -12.0% -16.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 65.9K 1.99M 1.82M 1.81M
Gross Profit 960.7K 880.3K 874.9K
Operating Income -2,392,032 -272,039 -249,417 -301,800
Net Income -2,396,269 -271,887 -219,394 -295,477
Gross Margin 48.2% 48.2% 48.2%
Operating Margin -3,628.6% -13.7% -13.7% -16.6%
Profit Margin -3,621.2% -13.7% -12.0% -16.3%
Rev Growth +6.4% +1.5% -4.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 297.1K 2.19M 1.92M 2.35M
Total Equity 5.75M 8.12M 8.19M 8.32M
D/E Ratio 0.05 0.27 0.23 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -2,095,224 -443,981 -374,843 -381,153
Free Cash Flow -242,138 -341,295 -221,285